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Abstract
Purpose To study the pharmacokinetics, pharmacodynam-
ics, and tolerability of rising single doses of macitentan, an
endothelin receptor antagonist, in healthy male subjects.
Methods This double-blind, placebo-controlled study was
performed in seven groups of eight healthy male subjects.
Doses of 0.2, 1, 5, 25, 100, 300 and 600 mg or placebo (two
subjectspergroup)wereadministered.Plasmamacitentanand
endothelin-1 and serum total bile salt concentrations were
measured and analysed non-compartmentally. Plasma and
urine were analysed qualitatively for the presence of
metabolites and one of these, ACT-132577, was also
measured quantitatively in plasma. Standard tolerability
measurements were performed throughout the study.
Results Macitentan was slowly absorbed and, at a dose of
300 mg, the t1/2 (95% confidence interval, CI) was 17.5 h
(14.1, 21.8). The dose-proportionality coefficient β for
Cmax (95% CI) was 0.83 (0.79, 0.87) indicating less than
dose-proportional pharmacokinetics of macitentan. In plasma,
a pharmacologically active oxidative depropyl metabolite,
ACT-132577, was found whereas in urine two minor metab-
olites were detected. The t1/2 of ACT-132577 (95% CI) was
65.6 h (53.1, 80.9). Macitentan dose-dependently increased
endothelin-1 concentrations up to 2.2-fold (95% CI 1.4, 2.4)
at a dose of 600 mg, but had no consistent effect on total bile
salts. Macitentan was well tolerated up to and including a
dose of 300 mg, the maximum tolerated dose. Headache,
nausea and vomiting were dose-limiting adverse events.
Conclusion The pharmacokinetic and tolerability profile of
macitentan is consistent with a once-a-day dosing regimen
and warrants further investigation in clinical studies.




Endothelin-1, which is synthesised predominantly by the
vascular endothelium, is one of the most potent and longest-
lasting vasoconstrictors known [1]. Elevated endothelin-1
levels have been found in numerous diseases, suggesting a
pathophysiological role of this peptide [2]. However, to date,
endothelin receptor antagonists such as bosentan have only
been approved for the treatment of pulmonary arterial
hypertension and systemic sclerosis and digital ulcer disease
whereas for other diseases either no therapeutic benefit could
be demonstrated or the benefit/risk ratio was judged to be
unfavourable [2, 3]. Risks related to treatment with
endothelin receptor antagonists include elevations in liver
aminotransferases and oedema [4]. The effects of endothelin
receptor antagonists on the liver are possibly a class effect
and necessitate monitoring of liver function in patients
treated with these compounds [5]. The recent withdrawal
from the market of the endothelin receptor antagonist
sitaxentan because of cases of unpredictable serious liver
injury, illustrates the need for compounds with a reduced
liver liability. Similarly, a reduced risk of oedema would
constitute a major advance and would allow for the
application of endothelin receptor antagonists in other
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darusentan in patients with treatment-resistant hypertension;
while darusentan provided additional reduction in blood
pressure in patients in whom hypertension could not be
controlled adequately with available drugs, oedema or fluid
retention occurred in 27% of the patients compared with
14% in patients treated with placebo [6].
The mechanism via which endothelin receptor antagonists
induce elevations in liver aminotransferases is unknown. It
has been hypothesised that inhibition of the bile salt export
pump (BSEP), an ABC transporter protein mediating secre-
tion of bile salts across the canalicular plasma membrane of
hepatocytes [7], results in intracellular accumulation of bile
salts and subsequent liver injury [8]. The occurrence of
oedema is possibly caused by circulating endothelin-1 via
activation of the endothelin B receptor [9], suggesting that
endothelin receptor antagonists that block both endothelin A
and B receptors are less prone to causing oedema. In fact, a
higher incidence of oedema was observed in patients with
pulmonary arterial hypertension treated with selective endo-
thelin receptor A antagonists, such as ambrisentan, compared
with dual receptor antagonists, such as bosentan [4].
In rats, intravenous administration of bosentan leads to
an acute increase in plasma bile salts (Actelion Pharma-
ceuticals, data on file) and this model was used to screen
new compounds. Compounds were further selected based
on their capacity to block both types of endothelin receptors
and a high octanol/aqueous buffer partition coefficient
indicative of a strong affinity for tissues. Macitentan
(ACT-064992, N-[5-(4-Bromophenyl)-6-(2-(5-bromopyri-
midin-2-yloxy)ethoxy)pyrimidin-4-yl]-N′-propylsulfamide)
is a new compound that inhibits endothelin receptors ETA
and ETB, but does not increase circulating bile salts in rats
(Actelion Pharmaceuticals, data on file). The structure of
macitentan is shown in Fig. 1. Macitentan is a lipophilic
compound with a volume of distribution of 1 l/kg and a half-
life of 2 h in rats. One circulating metabolite was identified,
ACT-132577, formed by oxidative depropylation of maci-
tentan, which has a similar volume of distribution, but a
longer half-life (8.5 h) [10]. It has been hypothesised that by
targeting endothelin receptors in tissues macitentan could
constitute an improved treatment of pulmonary arterial
hypertension or other diseases in which the tissue endothelin
system is activated [10]. The current entry-into-humans
study was performed to investigate the pharmacokinetics,
pharmacodynamics and tolerability of ascending single
doses of this new compound in healthy male subjects.
Materials and methods
ThestudyfollowedtheprinciplesoftheDeclarationofHelsinki
and Good Clinical Practice and the protocol was approved by
an independent Ethics Committee (Ethikkommission der
Ärztekammer Schleswig-Holstein, Bad Segeberg, Germany).
Written informed consent was obtained from all subjects prior
to study start.
Study design and subjects
This was a double-blind, randomised, placebo-controlled,
single-ascending-dose study in which each dose level was
investigated in a new group of eight healthy male subjects
(6 on active drug, 2 on placebo). Doses of 0.2, 1, 5, 25,
100, 300 and 600 mg of macitentan were compared with
placebo and the next higher dose was only administered
after review of the safety and tolerability findings of
subjects receiving the preceding dose. Subjects could only
receive one treatment and were not allowed to re-enter
another dose group. Subjects were healthy as assessed by
medical history, physical examination, ECG, vital signs and
clinical laboratory tests. They could not participate if they
smoked, had a prior history of drug or alcohol abuse, were
allergic to any drugs, were using any medication or had
participated in another clinical trial during the 3-month
period preceding the screening examination.
Study conduct
A screening examination was performed within 2 weeks of
study drug administration. Subjects were admitted to the
research unit approximately 12 h before study drug
administration, which was performed under fasted condi-




























Fig. 1 Chemical structure of macitentan and its main metabolite
ACT-132577
978 Eur J Clin Pharmacol (2011) 67:977–984after dosing. Later study assessments were done on an
ambulatory basis. During the study days, frequent recording
of vital signs and 12-lead ECG, evaluation of adverse
events, blood and urine sampling for clinical laboratory
testing and physical examination took place. The end-of-
study examination took place after the 48-h (dose groups
0.2 to 100 mg) or 144-h (dose groups 300 and 600 mg)
blood sample for pharmacokinetic and pharmacodynamic
purposes had been taken. An interim pharmacokinetic
analysis after the 25-mg dose group had been completed
revealed an unexpected long t1/2 of macitentan. In order to
fully characterise the elimination phase, the protocol was
amended to increase the time period of follow-up after
dosing from 48 h to 144 h. This change in protocol was
effective for the two higher dose groups only.
Sampling and bioanalytics
Plasma macitentan, its main metabolite, ACT-132577, and
endothelin-1 concentrations were determined in 4-ml venous
blood samples taken predose and at 0.33, 0.67, 1, 1.5, 2, 3, 4,
5, 6, 8, 10, 12, 16, 24, 30, 36, 48, 72, 96, 120 and 144 h after
dosing. The 72- to 144-h blood samples were only taken from
subjects having received the 300 and 600 mg doses. After
collection, the tubes containing EDTA as anticoagulant were
centrifuged for 10 min at 1,500 g and 4°C. The plasma was
separated and stored at −20°C pending analysis.
Serum total bile salts were measured in venous blood
samples taken predose and 1, 2, 3 and 4 h after dosing.
After collection, the tubes containing no anticoagulant were
left at room temperature for 30 min and subsequently
centrifuged for 10 min at 1,500 g and 4°C. The separated
serumwasstoredat−20°Cpendinganalysis.Nobloodsamples
for total bile salt measurements were taken at later time points
because subjects consumed a meal after the 4-h blood sample,
which was expected to affect these measurements.
Prior to the start of urine collection and at the end of each
collection interval, each subject was requested to completely
empty his bladder. Starting at dosing, total urine over four
consecutive 12-h intervals was collected in polyethylene
bottles, which were kept in the refrigerator. An aliquot of
10 ml was taken and stored at −20°C until analysis.
Plasma concentrations of macitentan and its active metab-
olite ACT-132577 were determined using a validated liquid
chromatography coupled to tandem mass spectrometry
method (LC-MS/MS). The assay was linear in the concentra-
tion range 1–2,000 ng/ml and the limit of quantification was
1.0 ng/ml for both analytes. The performance of the method
wasmonitoredusingqualitycontrolsamplesatconcentrations
of 3, 100 and 1,500 ng/ml. At these concentrations, precision
(%CV) was ≤7.1% for macitentan and ≤6.7% for ACT-
132577, whereas bias was ≤1.3% and ≤5.3% for macitentan
and ACT-132577 respectively.
Plasma concentrations of endothelin-1 were determined
using a commercially available radioimmunoassay (R & D
Systems Europe Ltd, Abingdon, UK; detection limit
0.25 pg/ml).
Total serum bile salts were measured using a commercially
available enzymatic assay (Sigma Bile Acids Method No#450,
TrinityBiotech,Darmstadt,Germany;detectionlimit1μmol/l).
Metabolic profiling
The presence of bromine atoms in the chemical structure of
macitentan (Fig. 1) facilitated the detection of both parent
and possible metabolites in plasma and urine. For this,
50 μl of plasma from the 2-, 6- and 48-h blood samples
from a subject in the 600-mg dose group were pooled and
proteins precipitated with an acetonitrile/ethanol mixture
(50/50, v/v). Similarly, 50 μl of urine from each collection
interval from two subjects in the 600-mg dose group were
pooled. Following centrifugation of both plasma and urine
at 3,360 g for 10 min at 8°C, 20 μl of the extracted sample
were injected onto the HPLC column (Atlantis dC18; Waters,
Milford, MA, USA). Detection was performed with a LTQ
Quantum mass spectrometer (ThermoFinnigan, San Jose, CA,
USA)andmetabolitesidentifiedwiththehelpoftheMetabolite
ID software (ThermoFinnigan, San Jose, CA, USA).
Data analysis
Safety and tolerability variables were analysed descriptively.
For this, subjects treated with placebo were pooled.
The pharmacokinetic variables Cmax,t max, AUC and t1/2
of macitentan and its metabolite as well as the AUC of
endothelin-1 (AUC0–48h) and total bile salts (AUC0–4h)
were determined by non-compartmental methods, as previ-
ously described [11]. Dose proportionality of macitentan
pharmacokinetics was only explored by comparing log-
transformed Cmax values using a power model described by
Gough et al. [12], as for most dose groups no reliable
estimate of AUC0−∞ could be determined because of the
unexpected long t1/2 of macitentan. The variables AUC0–48h
and AUC0–4h for endothelin-1 and total bile salts respec-
tively were compared between the different macitentan
doses and placebo using analysis of variance (ANOVA,




Fifty-six healthy male Caucasian subjects (age range: 19–
49 years, body weight range: 55.4–98.0 kg) participated in
Eur J Clin Pharmacol (2011) 67:977–984 979this study and all completed the study as per protocol. A
summary of the adverse events reported during the study,
including those adverse events judged to be unrelated to
study medication, is provided in Table 1. No unexpected
adverse events, signs of oedema and/or serious adverse
events were reported and all events resolved without
sequelae. Up to and including a dose of 300 mg, the
adverse event profile of macitentan did not significantly
differ from that of placebo, whereas more adverse events
than in the placebo group were reported at a dose of
600 mg. In this latter dose group, 5 out of 6 subjects
reported headache of moderate intensity, accompanied by
nausea and vomiting in 2 subjects. Two cases of increased
alanine aminotransferase to about 2 times the upper limit of
normal or less were observed: in a subject who had
received 600 mg of macitentan and the other in a subject
who had received placebo. Both cases occurred 7 days after
drug administration, whereas 48 h after administration liver
enzymes were normal. In neither subject was a significant
increase in aspartate aminotransferase, bilirubin or alkaline
phosphatase noted, nor were there any changes in total bile
salt concentrations. There were no clinically significant
drug-related effects on vital signs, ECG and clinical
laboratory variables.
Pharmacokinetics
The mean plasma concentration–time profiles and the
pharmacokinetic variables of macitentan and its main
metabolite are shown in Fig. 2, and Tables 2 and 3. Under
fasting conditions, macitentan was absorbed slowly with a
median tmax varying from 8 to 30 h for the different dose
groups. After attainment of Cmax, plasma concentrations
decreased slowly. The apparent terminal half-life could only
be reliably estimated for the two higher dose groups and
was about 16 h. The pharmacokinetics of macitentan
showed a less than dose-proportional increase for Cmax as
indicated by a value for the dose proportionality coefficient
β (95% CI) of 0.83 (0.79, 0.87). Formation of the depropyl
metabolite was slow with maximum concentrations attained
at least 30 h after dosing (Fig. 2, Table 3). In comparison to
the parentcompound,plasmaconcentrationsofthe metabolite
were higher and elimination was slower as demonstrated
by mean t1/2 v a l u e sv a r y i n gf r o m4 0 . 2t o6 5 . 6h .T h i s
resulted in a total exposure (AUC0−∞) to the metabolite that
was 2.7-fold (95% CI 2.5, 2.9) greater than that to
macitentan at a dose of 600 mg.
One subject in the 600-mg dose group was excluded
from the pharmacokinetic analysis because of an atypical
plasma concentration-time profile of both macitentan and
its metabolite. The Cmax values for parent and metabolite
were within the range observed for the other subjects, but
the elimination of both compounds was much slower.
Metabolic profiling
The investigation of the metabolic profile showed that in
plasma only two compounds could be identified containing
bromine atoms, macitentan and its metabolite, ACT-
132577. In urine, the presence of two other compounds
was shown, one that corresponds to a metabolite formed by
hydrolysis of either macitentan or ACT-132577, and the
other compound, based on the molecular weight, corresponds
to a glucoside analogue of ACT-132577. Because in urine no
macitentan and ACT-132577 could be detected, the collected
urine samples were not analysed for these compounds.
Pharmacodynamics
Plasma endothelin-1 concentrations dose-dependently
increased following administration of macitentan (Fig. 3)a n d
this effect was statistically significant for doses of 25 mg and
Adverse event Treatment (mg macitentan)
0.2 1 5 25 100 300 600 Placebo
Headache 0 0 0 2 1253
Back pain 0 0 0 0 0101
Hepatic function abnormal 0 0 0 0 0011
Nausea 0 0 0 0 0020
Rhinitis 0 0 0 0 0020
Vomiting 0 0 0 0 0020
Abdominal pain 0 0 0 0 0010
Flushing 0 0 0 0 0010
Leukocytosis 0 0 0 0 1000
Nasopharyngitis 0 0 0 1 0000
Neck pain 0 0 0 0 1000
Table 1 Overview of reported
adverse events by treatment
Number of subjects reporting
adverse events after having
received macitentan
(n=6 per dose) or placebo
(n=14)
Adverse events reported more
than once by the same subject
were counted once
980 Eur J Clin Pharmacol (2011) 67:977–984higher. The maximum effect was observed with the dose of
600 mg, which increased endothelin-1 concentrations 2.2-fold
(95% CI 1.4, 3.4) compared with placebo. Administration of
macitentan had no dose-dependent effect on serum total bile
salt concentration at single doses of up to 600 mg, although a
small but statistically significant effect (P<0.05) was observed
for the lowest dose (Fig. 3).
Discussion
This study has shown that single-dose administration of
macitentan in doses of up to and including 300 mg was well
tolerated in healthy male subjects. The dose-limiting
adverse events of headaches sometimes accompanied by
nausea and vomiting are well known for endothelin
receptor antagonists [13–15]. The maximum tolerated dose
of 300 mg is thought to be well above a clinically effective
dose, as based on endothelin-1 levels (see below). No
treatment-related effects on any safety assessment, includ-
ing liver function tests, were observed in this study. Two
cases of elevated alanine aminotransferase were detected in
this study. One subject was treated with 600 mg macitentan,
while the other subject was treated with placebo. It is not
uncommon to see elevations in liver aminotransferases in
phase I studies. In a pooled population from 13 phase I
studies in which a total of 93 healthy subjects were
administered placebo, 7.5% had at least one value of
alanine aminotransferase that was twice the upper limit of
normal [16]. Because of the small sample size in this study,
the clinical relevance of these findings and their relation-
ship to drug exposure is unknown, and has to be further
evaluated in subsequent clinical trials.
The risk of liver enzyme elevations in patients treated
with endothelin receptor antagonists may be a class effect
and necessitates monitoring of liver function. Recently, the
endothelin receptor antagonist sitaxentan was withdrawn
from the market because of unpredictable serious liver
injury. Preclinical models have demonstrated that some
endothelin receptor antagonists, including sitaxentan, are
substrates of and inhibit human hepatic transporters,
suggesting a mechanism for the increased hepatotoxicity






























































































Fig. 2 Arithmetic mean plasma concentration–time profiles of
macitentan (top panel) and ACT-132577 (bottom panel) in healthy
subjects (n=6 per group except for 600 mg dose where n=5) after
administration of a single dose of 0.2, 1, 5, 25, 100, 300 or 600 mg of
macitentan
Table 2 Pharmacokinetic variables of macitentan in healthy subjects after administration of a single dose of 0.2, 1, 5, 25, 100, 300 and 600 mg of
macitentan
Dose (mg) n Cmax (ng/ml) tmax (h) AUC0–48 (ng.h/ml) AUC0−∞ (ng.h/ml) t1/2 (h)
0.2 6 4.0 (2.6 to 6.2) 8 (8–12) 85.9 (52.4 to 141) ND ND
1 6 17.9 (12.4 to 25.9) 8 (4–10) 439 (271 to 711) ND ND
5 6 93.4 (79.1 to 110) 8 (4–8) 2056 (1,855 to 2,278) ND ND
25 6 335 (264 to 425) 8 (4–30) 8,810 (7,412 to 10,472) ND ND
100 6 999 (643 to 1552) 8 (4–12) 25,281 (18,775 to 34,040) ND ND
300 6 1,847 (1,409 to 2,422) 30 (10–48) 67,109 (48,751 to 92,380) 103,007 (76,650 to 138,428) 17.5 (14.1 to 21.8)
600 5* 2,967 (2,233 to 3,943) 12 (8–30) 96,530 (70,006 to 133,102) 127,104 (82,657 to 195,450) 13.4 (11.3 to 15.9)
Data are expressed as geometric means (and 95% CI) or for tmax the median (and range)
ND=not determined because t1/2 could not be reliably assessed
*One subject was excluded from the descriptive statistics because of an atypical plasma concentration–time profile
Eur J Clin Pharmacol (2011) 67:977–984 981observed with these agents [17]. In these models macitentan
did not inhibit human hepatic transporters (Actelion
Pharmaceuticals, data on file), suggesting that macitentan,
unlike other endothelin receptor antagonists, may not
induce cholestasis. In this study, serum total bile salt
concentrations were studied during a 4-h observation
period. During this time, administration of macitentan had
no effect on serum total bile salt concentrations, providing
some support that, in contrast to other endothelin receptor
antagonists, macitentan may be devoid of liver toxic effects
in man. It must be noted that both macitentan and ACT-
132577 have a long half-life and tmax occurring after the
end of the 4-h observation period and that macitentan was
administered as a single dose only. As elevations in liver
aminotransferases induced by endothelin receptor antago-
nists are typically seen after repeated dosing and sometimes
only after months of treatment [18], trials with longer
duration of treatment are needed to truly demonstrate a lack
of liver injury associated with macitentan.
The pharmacokinetics of macitentan were characterised
by slow absorption and elimination. The tmax in most
subjects was within the range 4 to 12 h, but was up to 48 h
in some. It is probably a chance finding that these latter
subjects were part of the 300-mg dose group leading to a
median tmax of 30 h, whereas it was 8 to 12 h in the other
dose groups. The t1/2 of macitentan and of its main
metabolite indicates that a once-a-day dosing regimen will
be appropriate for future studies. Such a regimen would
provide increased convenience for patients compared with
bosentan, which is dosed twice daily. The long t1/2 of
especially the depropyl metabolite suggests that accumula-
tion will occur upon repeated dosing with macitentan.
Accumulation factors of 1.7 and 10 are predicted for
macitentan and its metabolite respectively based on
simulation of multiple-dose profiles using the present
single-dose data (data not shown). This, together with the
observed higher exposure to the metabolite compared with
the parent compound after single-dose administration
indicates that the metabolite will contribute to a significant
extent to the pharmacological activity of macitentan. It
should be noted, however, that ACT-132577 is a less potent
Table 3 Pharmacokinetic variables of ACT-132577 in healthy subjects after administration of a single dose of 0.2, 1, 5, 25, 100, 300 and 600 mg
of macitentan
Dose (mg) n Cmax (ng/ml) tmax (h) AUC0–48 (ng.h/ml) AUC0−∞ (ng.h/ml) t1/2 (h)
0.2 6 3.7 (2.6 to 5.2) 36 (30–48) 114 (77.8 to 168) ND ND
1 6 16.3 (12.6 to 21.2) 48 (30–48) 527 (415 to 670) ND ND
5 6 84.1 (74.2 to 95.4) 33 (30–48) 2,540 (2,117 to 3,048) ND ND
25 6 304 (271 to 342) 42 (30–48) 9,146 (7,297 to 11,463) ND ND
100 6 931 (674 to 1,287) 42 (30–48) 32,068 (22,727 to 45,249) ND ND
300 6 2,585 (1,759 to 3,798) 48 (48–72) 67,174 (45,343 to 99,515) 330,549 (257,489 to 424,340) 65.6 (53.1, 80.9)
600 5* 3,688 (2,591 to 5,249) 48 (36–48) 104,968 (73,339 to 150,238) 342,084 (213,414 to 548,331) 40.2 (34.6, 46.7)
Data are expressed as geometric means (and 95% CI) or for tmax the median (and range)
ND=not determined because t1/2 could not be reliably assessed
*One subject was excluded from the descriptive statistics because of an atypical plasma concentration–time profile




























































































Fig. 3 Arithmetic mean (±SD) plasma endothelin-1 (top panel)a n d
serum total bile salt (bottom panel) concentrations in healthy subjects
after administration of a single dose of 0.2, 1, 5, 25, 100, 300 or 600 mg
of macitentan (n= 6p e rd o s eg r o u p )o rp l a c e b o( n=14). *P<0.05
compared with placebo
982 Eur J Clin Pharmacol (2011) 67:977–984endothelin receptor antagonist than macitentan in both
receptor binding and functional assays [10].
The pharmacokinetics of macitentan were less than dose
proportional over the wide dose range investigated. However,
dose-normalized Cmax values were similar for doses up to
5 mg, but decreased at higher doses (data not shown). It is
expected that the small deviation from dose proportionality
will not be of clinical relevance, but this remains to be
demonstrated.
For an as yet unknown reason, one subject eliminated
macitentan and its depropyl metabolite only very slowly. Of
note, the reported case of elevated alanine aminotransferase
in the 600-mg dose group did not occur in this subject.
Administration of 600 mg of macitentan was well tolerated
by this subject who did not report adverse events or
abnormal findings in any of the other safety assessments.
Further, review of the pharmacodynamic data of this
subject did not indicate relevant differences compared with
the other subjects treated with the same dose. Due to the
small sample size of six subjects per dose, it is not clear
whether this is an isolated finding, a sample handling error,
or whether this reflects a population heterogeneity in
clearance of macitentan and ACT-132577. The collection
of pharmacokinetic data in further studies will help to
investigate this further. In current clinical development the
highest dose used in multiple-dose treatment regimens is
10 mg of macitentan once daily. With over 150 healthy
subjects tested in the phase I program, no further cases of
atypical plasma concentration–time profiles have been
observed. Therefore, it is unlikely that genetic polymor-
phism in drug disposition is associated with clinically
relevant differences in pharmacokinetics of macitentan and
ACT-132577 in a therapeutic dose range.
The metabolic profiling experiments indicated the
presence of one major depropyl metabolite, ACT-132577,
in plasma and of two minor metabolites in urine and the
absence of the parent compound and ACT-132577 in urine.
It should be noted that the sensitivity of the method used to
detect possible metabolites is limited, which may explain
why metabolites were found in urine but not in plasma.
Further, less abundant metabolites may have been missed,
as well as those without bromine atoms. This type of
metabolic profiling may be useful in early clinical devel-
opment in order to quickly obtain information on metabo-
lism, but it cannot replace a dedicated study with a
radiolabelled compound. Preclinical experiments have
shown the presence of ACT-132577 in rat in which it was
the only circulating metabolite, and that it has affinity for
ETA and ETB receptors, although its affinity is lower than
that of macitentan for these receptors. In ex vivo experiments
using isolated rat aortic and tracheal preparations, it was
shown that, compared with macitentan, the metabolite was up
to 5-fold less potent in blocking ETA and ETB receptors [10].
Macitentan caused a dose-dependent but modest increase
in the plasma concentrations of endothelin-1, similar to that
of bosentan albeit with greater potency [15]. The increase
in endothelin-1 by endothelin receptor antagonists is
thought to be caused by blockade of ETB receptors, which
are responsible for the clearance of endothelin-1 at the level
of the lung [19]. Macitentan and ACT-132577 are about 50-
and 16-fold respectively, more selective for ETA receptors
than for ETB receptors [10] and at macitentan doses that
increase endothelin-1, it is thus expected that the ETA
receptor will be fully blocked. Although there is an ongoing
debate on the advantages and disadvantages of blocking
ETB receptors in patients, there does not appear to be a
major difference in clinical efficacy in treating patients with
pulmonary arterial hypertension between selective ETA
receptor antagonists and dual ETA and ETB receptor
antagonists [20, 21]. However, a head-to-head comparison
has not, as yet, been performed. From the present results it
may be deduced that 25 mg will be a clinically relevant
macitentan dose, i.e. the lowest dose that significantly
increased plasma endothelin-1 concentrations in this study
and thus fully blocks ETA receptors. Taking the expected
accumulation into account upon multiple dosing, clinically
relevant doses are possibly lower.
In summary, single-dose administration of macitentan, a
new endothelin receptor antagonist designed to be devoid of
liver injury, was well tolerated up to doses of 300 mg
and its pharmacokinetic characteristics are consistent with
once-a-day dosing. This safety and pharmacokinetic profile
warrantsfurtherinvestigationofmacitentaninclinicalstudies.
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